Popular Articles

Jamal Mecklai: Has RBI been diversifying out of dollars?
Jamal Mecklai / New Delhi November 27, 2009, 0:29 IST

RNRL Q3 net up 3% to Rs 25 cr
Anil Ambani Group firm Reliance Natural Resources (RNRL) today reported growth of 3.30 per cent in net profit at Rs 25 crore for the third quarter ended December 31, 2009, over the same period last year.

News of the day

VC investments in India dip 72% to $117 mn in H109
The global economic downturn has cast its shadow on venture capital investments in India which have slumped 72 per cent to $117 million in the first 6 months of the current year.
Small Business

India Eco Summit: Pfizer to launch another product in India

World"s largest drug maker Pfizer today said it is in the process of bringing in synergies in operation with Wyeth, which it acquired in January this year, and will launch one more product by the end of this fiscal. - India Eco Summit: Sharma pitches for stimulus continuation - India Eco Summit: Fortis Healthcare to set up 3 more hospitals - India Eco Summit: "India at bottom half in man-woman equality index" - India Eco Summit: Ispat-Stemcor Rs 1,100-cr project to start soon - India Eco Summit: Kingfisher Airlines to raise $600 mn - India Eco Summit: ICICI to reduce stake in Firstsource "We have already introduced three products in the country in the last few months. Going forward we will be introducing one more product by the end of the current fiscal," Pfizer India Managing Director Keval Handa told reporters here on the sidelines of the India Economic Summit. Pfizer has recruited around 250 people this year for its India operations and will add another 200 to its tally next year. The company is also planning to expand to smaller cities. "To fuel the growth of Pfizer in India, we are also expanding our operations in tier-2 and tier-3 cities," Handa added. In January, Pfizer had acquired much smaller rival Wyeth for about $68 billion. Handa has also been appointed as Managing Director of Wyeth"s India operations. "As of now, Wyeth and Pfizer are two separate entities and they do not have major overlaps in terms of product portfolios and rather they complement each other," he added. The company is currently working on bringing synergies in operations of Pfizer and Wyeth in the country, he said. Asked about merger of Wyeth with Pfizer, Handa declined to comment.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):